Comparative analysis of triplex nucleic acid test assays in United States blood donors
- 17 October 2013
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 53 (10pt2) , 2525-2537
Abstract
Background: This study assessed the clinical sensitivity of three fully automated, human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) triplex nucleic acid test (NAT) assays by individual donation (ID‐NAT) and at operational minipool (MP‐NAT) sizes used worldwide.Study Design and Methods: MPX, Ultrio, and Ultrio Plus were used to test 2222 pedigreed, marker‐positive samples with varying viral loads, each from a unique US blood donor. NAT‐positive, seronegative yield samples (16 HBV, 156 HCV, and 23 HIV) were tested in replicates of three; undiluted; and in 1:6, 1:8, and 1:16 dilutions (MP6, MP8, and MP16), simulating various MP sizes. Seropositive samples (1276 HBV, 488 HCV, and 263 HIV) were tested by ID‐NAT in singlet.Results: MPX‐MP6 and Ultrio Plus‐MP16 had equivalent HCV sensitivity. Although Ultrio Plus‐MP16 for HIV trended toward lesser sensitivity, this was not corroborated in a large substudy of low‐viral‐load samples in which Ultrio Plus‐MP8/MP16 showed 100% reactivity. MPX‐ID and Ultrio Plus‐ID HBV clinical sensitivity were identical, but MPX‐MP6 was significantly more sensitive than Ultrio Plus‐MP16; the differential yield projected to one HBV NAT yield per 4.72 million US donations. Ultrio Plus HBV sensitivity did not increase at MP8 versus MP16. Ultrio Plus versus Ultrio sensitivity was significantly increased in HBV‐infected donors with early acute, late acute or chronic, and occult infections. No difference in sensitivity was noted for any virus for MPX‐MP6 versus Ultrio Plus‐ID.Conclusions: Our data support US donation screening with MPX‐MP6 or Ultrio Plus‐MP16 since the HBV DNA detection of Ultrio Plus was significantly enhanced (vs. Ultrio) without compromising HIV or HCV RNA detection.Keywords
This publication has 32 references indexed in Scilit:
- International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009Vox Sanguinis, 2011
- Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?Transfusion, 2011
- Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yieldTransfusion, 2011
- Nucleic Acid Testing to Detect HBV Infection in Blood DonorsNew England Journal of Medicine, 2011
- Occult hepatitis B virus infection in Thai blood donorsTransfusion, 2011
- Current incidence and residual risk of hepatitis B infection among blood donors in the United StatesTransfusion, 2009
- One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donationsTransfusion, 2009
- Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti‐HCV, anti‐HIV, and p24/anti‐HIV combination assays in seroconversion panelsTransfusion, 2009
- Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNATransfusion, 2007
- Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification TestingNew England Journal of Medicine, 2004